Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management

Overview

Journal Case Rep Oncol

Publisher Karger

Specialty Oncology

Date 2017 Dec 28

PMID 29279690

Citations 34

Authors

Jonathan Kapke

Zachary Shaheen

Deepak Kilari

Paul Knudson

Stuart Wong

Affiliations

Soon will be listed here.

Abstract

With the introduction of immune checkpoint inhibitors into clinical practice, various autoimmune toxicities have been described. Antibodies targeting the receptor:ligand pairing of programmed death receptor-1 (PD-1) and its cognate ligand programmed death-ligand 1 (PD-L1) in rare reports have been associated with autoimmune diabetes mellitus. We report 2 cases of rapid-onset, insulin-dependent, type 1 diabetes mellitus in the setting of administration of nivolumab, a fully human monoclonal antibody to PD-1, and atezolizumab, a humanized monoclonal antibody to PD-L1. This appears to be the first report of autoimmune diabetes mellitus associated with atezolizumab. In addition, we provide a brief review of similar cases reported in the literature and a discussion of potential mechanisms for this phenomenon and propose a diagnostic and treatment algorithm.

Citing Articles

Pathophysiology, diagnosis, and management of immune checkpoint inhibitor-induced diabetes mellitus.

Kani E, Karaviti E, Karaviti D, Gerontiti E, Paschou I, Saltiki K Endocrine. 2024; 87(3):875-890.

PMID: 39316333 DOI: 10.1007/s12020-024-04050-5.

Nivolumab-Induced Diabetic Ketoacidosis: A Case Report.

Giese D, Elkhedr A, Jnaneswaran G, Ernste K Cureus. 2024; 16(7):e64319.

PMID: 39130825 PMC: 11316834. DOI: 10.7759/cureus.64319.

Immune checkpoint inhibitors-induced diabetes mellitus (review).

Chen J, Hou X, Yang Y, Wang C, Zhou J, Miao J Endocrine. 2024; 86(2):451-458.

PMID: 38955861 DOI: 10.1007/s12020-024-03942-w.

Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria.

Angelousi A, Ziogas D, Siampanopoulou V, Mytareli C, Anastasopoulou A, Lyrarakis G Diseases. 2024; 12(2).

PMID: 38391787 PMC: 10887699. DOI: 10.3390/diseases12020040.

Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.

Daetwyler E, Zippelius A, Danioth S, Donath M, Gut L Front Immunol. 2023; 14:1248919.

PMID: 37965350 PMC: 10640970. DOI: 10.3389/fimmu.2023.1248919.

References

McCulloch D, Palmer J . The appropriate use of B-cell function testing in the preclinical period of type 1 diabetes. Diabet Med. 1991; 8(9):800-4. DOI: 10.1111/j.1464-5491.1991.tb02116.x. View

Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H . Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8(5):765-72. DOI: 10.1093/intimm/8.5.765. View

Gale E . Can we change the course of beta-cell destruction in type 1 diabetes?. N Engl J Med. 2002; 346(22):1740-2. DOI: 10.1056/NEJM200205303462211. View

Teramoto Y, Nakamura Y, Asami Y, Imamura T, Takahira S, Nemoto M . Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol. 2016; 44(5):605-606. DOI: 10.1111/1346-8138.13486. View

Nguyen C, Varney M, Harrison L, Morahan G . Definition of high-risk type 1 diabetes HLA-DR and HLA-DQ types using only three single nucleotide polymorphisms. Diabetes. 2013; 62(6):2135-40. PMC: 3661605. DOI: 10.2337/db12-1398. View

Klinke 2nd D . Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One. 2008; 3(1):e1374. PMC: 2147725. DOI: 10.1371/journal.pone.0001374. View

Gaudy C, Clevy C, Monestier S, Dubois N, Preau Y, Mallet S . Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes. Diabetes Care. 2015; 38(11):e182-3. DOI: 10.2337/dc15-1331. View

Tisch R, McDevitt H . Insulin-dependent diabetes mellitus. Cell. 1996; 85(3):291-7. DOI: 10.1016/s0092-8674(00)81106-x. View

Munakata W, Ohashi K, Yamauchi N, Tobinai K . Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol. 2016; 105(3):383-386. DOI: 10.1007/s12185-016-2101-4. View

10.

Mallone R, Martinuzzi E, Blancou P, Novelli G, Afonso G, Dolz M . CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes. 2007; 56(3):613-21. DOI: 10.2337/db06-1419. View

11.

Butte M, Keir M, Phamduy T, Sharpe A, Freeman G . Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27(1):111-22. PMC: 2707944. DOI: 10.1016/j.immuni.2007.05.016. View

12.

Morran M, Vonberg A, Khadra A, Pietropaolo M . Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med. 2015; 42:42-60. PMC: 4548800. DOI: 10.1016/j.mam.2014.12.004. View

13.

Hansen E, Sahasrabudhe D, Sievert L . A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016; 65(6):765-7. PMC: 11028850. DOI: 10.1007/s00262-016-1835-4. View

14.

Atkinson M, Eisenbarth G . Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001; 358(9277):221-9. DOI: 10.1016/S0140-6736(01)05415-0. View

15.

Zamani M, Aslani S, Salmaninejad A, Javan M, Rezaei N . PD-1/PD-L and autoimmunity: A growing relationship. Cell Immunol. 2016; 310:27-41. DOI: 10.1016/j.cellimm.2016.09.009. View

16.

Hofmann L, Forschner A, Loquai C, Goldinger S, Zimmer L, Ugurel S . Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016; 60:190-209. DOI: 10.1016/j.ejca.2016.02.025. View

17.

Conrad B, Trucco M . Superantigens as etiopathogenetic factors in the development of insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1994; 10(4):309-38. DOI: 10.1002/dmr.5610100402. View

18.

Okazaki T, Honjo T . The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006; 27(4):195-201. DOI: 10.1016/j.it.2006.02.001. View

19.

Martin-Liberal J, Furness A, Joshi K, Peggs K, Quezada S, Larkin J . Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015; 64(6):765-7. PMC: 11028478. DOI: 10.1007/s00262-015-1689-1. View

20.

Bluestone J, Tang Q . How do CD4+CD25+ regulatory T cells control autoimmunity?. Curr Opin Immunol. 2005; 17(6):638-42. DOI: 10.1016/j.coi.2005.09.002. View